The US Host Cell Protein Testing Market is positioned for steady expansion as demand for biologic medicines and advanced quality-control solutions continues to increase. The market is estimated at USD 220.8 million in 2024 and is forecast to reach USD 409.33 million by 2035, growing at a CAGR of 5.77%. Regulatory scrutiny, product safety awareness, and innovation in analytical testing are expected to remain major growth factors. 

The expansion of biopharmaceutical manufacturing facilities across the United States is creating additional demand for comprehensive testing capabilities. New and upgraded facilities require modern analytical infrastructure to support manufacturing processes and regulatory compliance. This trend is particularly relevant as companies increase production capacity for biologics, vaccines, and other advanced therapies.

Testing technology is also evolving rapidly. PCR-based assays remain the dominant category, while ELISA-based methods are expanding because of their flexibility and cost-effectiveness. Advanced mass spectrometry and chromatography techniques are helping laboratories improve the detection and measurement of host cell proteins. Meanwhile, the growing use of CRO services is providing manufacturers with access to specialized expertise without requiring all testing capabilities internally. 

Over the long term, automated workflows, high-throughput screening, artificial intelligence, and improved data-analysis tools could transform host cell protein testing. Companies that combine technological innovation with regulatory expertise and reliable service delivery will be well positioned to capture emerging opportunities. With continued growth in biopharmaceutical development and manufacturing, the U.S. market should remain an important center for host cell protein testing through 2035.